Latanoprost

Evidence Level: L5

Predicted Indications: 9

Latanoprost

Pharmacist Assessment Report

Latanoprost: Visceral calciphylaxis

One-Sentence Summary

Latanoprost is a prostaglandin F2-alpha analogue eye drop, originally used for open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for visceral calciphylaxis, but currently there are 0 clinical trials and 0 publications in the data compiled for this report, so this is a model prediction only.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	Visceral calciphylaxis
TxGNN Prediction Score	0.9983
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, latanoprost is a prostaglandin F2-alpha analogue that lowers intraocular pressure (IOP) by increasing uveoscleral outflow.

There are caveats. Developmental defects in the outflow pathway in congenital forms may reduce the response to treatment. Paediatric use would also need separate safety and efficacy review. No trials or publications support the link at this stage.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 14453Q	Xalatan	Eye drops 50 micrograms per mL, 2.5 mL	Not recorded in the data compiled

Safety Considerations

Disease contraindications flagged in the knowledge graph (not taken from label text): uveitis, iris disease, ciliary body disease, panuveitis, macular retinal edema, cystoid macular edema, iritis, conjunctivitis and acute contagious conjunctivitis.
Drug Interactions: 100 potential interactions were identified in the DDI database, but none has a severity level assigned. Examples include calcitriol, glimepiride, doxycycline, clotrimazole, lansoprazole, cimetidine, atropine, pantoprazole, mesalazine and acarbose. These should be interpreted with caution given latanoprost’s minimal systemic exposure as a topical ophthalmic agent.

Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Other Predicted Indications (Context)

All of the top 10 predictions have Evidence Level L5, with no supporting trials or literature.

Rank	Predicted Indication	TxGNN Score	Assessment
2	Visceral calciphylaxis	0.9983	No clear mechanistic link
3	Hypotrichosis simplex of the scalp	0.9981	Biologically plausible (prostaglandin analogues stimulate hair growth; a related analogue is approved for eyelash hypotrichosis), but the genetic follicular defect may not respond. May merit a focused literature search
4–6	Venous, arterial and neurogenic thoracic outlet syndrome	99.72–0.9978	No credible mechanistic link (mechanical compression disorders)
7	Congenital hypotrichosis milia	0.9971	Similar rationale to rank 3, but a rare congenital disorder
8	Angiodysplasia of stomach	0.9970	No credible link; vasodilation could be undesirable in a bleeding lesion
9	Blue toe syndrome	0.9969	Speculative only; topical dosing gives no relevant systemic exposure
10	Lymphangiectasis	0.9967	Too indirect to support a hypothesis

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is mechanistically reasonable but is supported by model output alone, with no registered trials or publications. It is also essentially an extension of existing glaucoma use. The package insert safety data for Australia could not be retrieved, which blocks safety screening.

To proceed, the following is needed:

Retrieve and review the Australian Product Information (warnings, contraindications and approved indication text for Xalatan)
Mechanism of action data (for example, from DrugBank)
A targeted literature and trial registry search (including ANZCTR) for latanoprost in primary congenital or hereditary glaucoma
Paediatric safety and efficacy review, as hereditary glaucoma commonly presents in infancy
A focused literature search on prostaglandin analogues for hypotrichosis, as the most biologically plausible non-glaucoma candidate
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.